With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
This article was originally published in The Pink Sheet Daily
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
You may also be interested in...
The BioVentures VI fund will invest across the life sciences sector in Europe and the U.S. and could herald an uptick in VC fundraising activity.
A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.
Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.